Program
Anti-PD-1/LAG-3 Bispecific Antibody AK129
Also written as “Drug: AK129 Drug:oxaliplatin Drug:capecitabine”, “Drug: AK129 Drug: cadonilimab Drug: oxaliplatin Drug: capecitabine” and “AK129 IV infusion”.
Its studies are mostly in Squamous Cell Carcinoma of Head and Neck · Hodgkin Disease, led by Akeso.
Drug pageAnti-PD-1/LAG-3 Bispecific Antibody AK129: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Akeso | 42 open or running | phase 2since Sep 4, 2024 | Nov 17, 2022 | Dec 2026phase 2 · NCT06943820 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 17, 2022First study: phase 1 study in Advanced Malignant Tumors(Stage IA-IB)First studyNCT05645276 · 57 enrolled · China
- Sep 4, 20242 phase 2 studiesNCT06586294, NCT06642792
- Apr 6, 2025Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06943820 · 230 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06943820
- Nov 2027Primary completion: phase 2 study in Classic Hodgkin LymphomaNCT06642792
TargetBeta
“A humanized, immunoglobulin G1 (IgG1) bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PD1; PDCD1; CD279; programmed death 1) and lymphocyte activation gene 3 protein (LAG-3; LAG3; CD223), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| TQB2252 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06943820Squamous Cell Carcinoma of Head and Neck · China | 2 | Recruiting | Dec 2026 | 230 |
| NCT06642792Classic Hodgkin Lymphoma · China | 2 | Recruiting | Nov 2027 | 280 |
| NCT06586294Gastric Adenocarcinoma · China | 2 | Completed | Apr 20, 2026 | 35 |
| NCT05645276Advanced Malignant Tumors(Stage IA-IB) · China | 1 | Completed | Jun 9, 2026 | 57 |
How it is read
Names in the registry
- “Drug: AK129 Drug:oxaliplatin Drug:capecitabine”, 1 entry
- “Drug: AK129 Drug: cadonilimab Drug: oxaliplatin Drug: capecitabine”, 1 entry
- “AK129 IV infusion”, 1 entry
- “AK129(dose 1)”, 1 entry
- “AK129(dose 2)”, 1 entry
Conditions, from the studies’ own filings
- Squamous Cell Carcinoma of Head and Neck, 1 study
- Hodgkin Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.